**Author details**

Danijela Štrbac1 , Katja Goričar2 , Viljem Kovač1 and Vita Dolžan<sup>2</sup> \*

1 Institute of Oncology Ljubljana, Ljubljana, Slovenia

2 Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

\*Address all correspondence to: vita.dolzan@mf.uni-lj.si

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**37**

*Current Mesothelioma Treatment and Future Perspectives*

[7] Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer. 2009;64(3):308-313. DOI: 10.1016/j.

[8] Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26 Suppl 5:v31-39. DOI: 10.1093/annonc/mdv199

[9] Kindler HL, Ismaila N, Armato SG, 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 2018;36(13):1343-1373. DOI: 10.1200/

Dolzan V. Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Scientific Reports. 2017;7:46537. DOI: 10.1038/srep46537

[11] O'Brien ME, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective

validation of progression free survival

mesothelioma clinical trials (European

Treatment of Cancer 08052). European Journal of Cancer. 2013;49(13):2815- 2822. DOI: 10.1016/j.ejca.2013.05.008

Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma

rate as a primary end-point for

Organisation for Research and

[12] Zalcman G, Mazieres J,

lungcan.2008.09.008

JCO.2017.76.6394

[10] Goricar K, Kovac V,

*DOI: http://dx.doi.org/10.5772/intechopen.94246*

[1] Sugarbaker DJ, Heher EC, Lee TH, Couper G, Mentzer S, Corson JM, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. Journal of Thoracic and Cardiovascular Surgery. 1991;102(1):

**References**

10-14; discussion 14-15.

10.3816/CLC.2010.n.005

[3] Ettinger DS, Wood DE,

Insights: Malignant Pleural

10.6004/jnccn.2016.0087

[4] Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Populationbased survey of 444 patients. Radiology and Oncology. 2012;46(2):136-144. DOI: 10.2478/v10019-012-0032-0

[5] Damhuis RA, Schroten C,

for malignant mesothelioma after introduction of novel

Burgers JA. Population-based survival

chemotherapy. European Respiratory Journal. 2012;40(1):185-189. DOI: 10.1183/09031936.00153611

Marin A, Debeljak A, Smrdel U, et al. A phase II trial of low-dose gemcitabine

[6] Kovac V, Zwitter M, Rajer M,

in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anti-Cancer Drugs. 2012;23(2):230-238. DOI: 10.1097/

CAD.0b013e32834d7a1c

Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN Guidelines

Mesothelioma, Version 3.2016. Journal of the National Comprehensive Cancer Network. 2016;14(7):825-836. DOI:

[2] Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clinical Lung Cancer. 2010;11(1):30-35. DOI:

*Current Mesothelioma Treatment and Future Perspectives DOI: http://dx.doi.org/10.5772/intechopen.94246*
